Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Randomized Phase II Study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ABIDO; ABIDO-SOGUG
- 20 Sep 2019 Planned End Date changed from 1 Feb 2020 to 1 Jan 2020.
- 20 Sep 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Jan 2020.
- 31 Aug 2018 Biomarkers information updated